
Ongoing shortages of a medication that hospitals and emergency rooms rely upon to treat breathing problems are likely to worsen in coming days and weeks, experts warn. That’s because one of the two major U.S. suppliers of liquid albuterol, Akorn Pharmaceuticals, abruptly laid off its entire workforce and closed plants in New Jersey, New York and Illinois in late February. “We’re down to just one plant that’s supplying liquid albuterol to all patients in the United States,” said Dr. Juanita Mora, a Chicago allergist/immunologist and volunteer spokesperson for the American Lung Association. That remaining supplier of liquid albuterol, Nephron Pharmaceuticals, has had manufacturing issues of its own, exacerbating the situation even more, said Bayli Larson, a strategic initiatives associate with the American Society of Health-System Pharmacists (ASHP). “Another phenomenon that could be at play is institutions, anticipating the shortage, may have increased their orders to ensure they had enough on hand,” Larson added. “ASHP discourages hoarding as a countermeasure to medication supply disruptions; however, some institutions feel they have to do it to avoid jeopardizing patient care.” The shortage comes at an extremely inopportune time, Mora said. “We are about to enter allergic asthma season, where pollen levels are going to begin to rise all throughout the United States,” Mora said. “And we know so many kids and adults suffer from allergic asthma symptoms and… read on > read on >